title: Lithium Pharmacogenetics: Where Do We Stand?
abstract: Preclinical Research Bipolar disorder (BPD) is a chronic and disabling psychiatric disorder with a prevalence of 0.8-1.2% in the general population. Although lithium is considered the first-line treatment, a large percentage of patients do not respond sufficiently. Moreover, lithium can induce severe side effects and has poor tolerance and a narrow therapeutic index. The genetics of lithium response has been largely investigated, but findings have so far failed to identify reliable biomarkers to predict clinical response. This has been largely determined by the highly complex phenotipic and genetic architecture of lithium response. To this regard, collaborative initiatives hold the promise to provide robust and standardized methods to disantenagle this complexity, as well as the capacity to collect large samples of patietnts, a crucial requirement to study the genetics of complex phenotypes. The International Consortium on Lithium Genetics (ConLiGen) has recently published the largest study so far on lithium response reporting significant associations for two long noncoding RNAs (lncRNAs). This result provides relevant insights into the pharmacogenetics of lithium supporting the involvement of the noncoding portion of the genome in modulating clinical response. Although a vast body of research is engaged in dissecting the genetic bases of response to lithium, the several drawbacks of lithium therapy have also stimulated multiple efforts to identify new safer treatments. A drug repurposing approach identified ebselen as a potential lithium mimetic, as it shares with lithium the ability to inhibit inositol monophosphatase. Ebselen, an antioxidant glutathione peroxidase mimetic, represents a valid and promising example of new potential therapeutic interventions for BD, but the paucity of data warrant further investigation to elucidate its potential efficacy and safety in the management of BPD. Nevertheless, findings provided by the growing field of pharmacogenomic research will ultimately lead to the identification of new molecular targets and safer treatments for BPD. Drug Dev Res 77 : 368-373, 2016. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Pisanu
authors.affiliation: Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Italy.
authors.forename: Carla
authors.initials: C
authors.lastname: Melis
authors.affiliation: Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Italy.|Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Alessio
authors.initials: A
authors.lastname: Squassina
mesh_terms: D000818:Animals; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001393:Azoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D054833:Isoindoles; D018020:Lithium Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D016566:Organoselenium Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010597:Pharmacogenetics; D062085:RNA, Long Noncoding / Q000235:genetics
chemical_list: D018692:Antimanic Agents; D001393:Azoles; D015415:Biomarkers; D054833:Isoindoles; D018020:Lithium Compounds; D016566:Organoselenium Compounds; D062085:RNA, Long Noncoding; C042986:ebselen
keywords: bipolar disorder; ebselen; lithium; mood stabilizers; pharmacogenetics